#None #Paris #Psoriasis #EADV Congress #GLP-1RAs

Advancements in Psoriasis Treatment: GLP-1RAs and Cardiovascular Safety

The European Academy of Dermatology and Venereology (EADV) Congress 2025 has unveiled compelling research demonstrating the potential of GLP-1 receptor agonists (GLP-1RAs) in treating patients with psoriasis. The study indicates that these medications not only aid in weight management and diabetes control but also considerably lower the risk of cardiovascular events and mortality in individuals suffering from this chronic skin disease.

Psoriasis, a chronic inflammatory condition affecting 2-3% of the global population, is associated with both physical and psychological complications, increasing susceptibility to serious conditions such as heart attacks and strokes. In a major presentation at EADV 2025, findings revealed that psoriasis patients treated with GLP-1RAs experienced a 78% reduction in mortality risk and a 44% decrease in significant cardiovascular events when compared to those undergoing treatment with other diabetes or anti-obesity drugs.

The study, which is the largest of its kind to date, analyzed a dataset from over 110 million U.S. patients. Researchers observed more than 6,000 subjects with psoriasis, diabetes, or obesity over two years, with a balanced group of 3,048 patients each receiving GLP-1RAs versus other medications. Adjustments for age, sex, and additional health conditions provided clear evidence supporting the benefits of GLP-1RAs in enhancing cardiovascular outcomes.

Professor Ralf Ludwig, the principal investigator, shared insights, stating, "Our findings suggest that GLP-1 receptor agonists could provide significant advantages beyond weight control and glucose management. Notably, they may improve cardiovascular and psychiatric results in psoriasis patients. We hypothesize that GLP-1 receptor activation could inhibit pro-inflammatory mediators that are elevated in psoriasis patients. Furthermore, these receptors are also found in brain regions connected to mood and reward systems, which might account for the observed reductions in alcohol and substance use."

The study reports substantial benefits specifically for psoriasis patients, hinting at a synergistic relationship between systemic inflammation and the mechanisms through which GLP-1RAs operate. Importantly, safety results mirrored those found in the general population, with no significant uptick in adverse effects like hypoglycemia, nausea, or constipation.

Given their acceptable safety profile and variety of positive outcomes, GLP-1RAs could emerge as a front-line therapy for individuals with psoriasis who also require diabetes management or weight management strategies. This breakthrough illustrates a promising future for psoriasis treatments by integrating GLP-1 receptor agonists into therapeutic protocols.

As we continue to witness advancements in dermatological healthcare, these findings shine a light on the importance of addressing both physical and mental health care needs for patients afflicted with psoriasis, offering them a chance for a healthier and more fulfilling life.